NCT02592421View on ClinicalTrials.gov

SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 23, 2015

Primary Completion Date

October 1, 2018

Study Completion Date

October 31, 2019

Conditions
Type II Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

SGLT2 inhibitor (dapagliflozin)

DRUG

Placebo

Placebo Comparator

Trial Locations (1)

78229

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02592421 - SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2 | Biotech Hunter | Biotech Hunter